Searchable abstracts of presentations at key conferences in endocrinology

ea0029p483 | Developmental endocrinology | ICEECE2012

GH replacement therapy in patients with primary paediatric brain tumours

Seregni E. , Pallotti F. , Biassoni V. , Catania S. , Gandola L. , Spreafico F. , Terenziani M. , Mallia A. , Bombardieri E. , Massimino M.

Aim: Endocrinopathies are frequent complications in paediatric patients with primary brain tumours (PBT) and among them GH deficiency (GHD) is of particular relevance. In this study we evaluated the incidence of GHD and the impact of GH therapy in a large series of PBT bearing patients or adult patients previously treated for PBT.Methods: From January 2001 to December 2011 more than 700 PBT patients were screened for endocrine complications. GHD was expl...

ea0029p788 | Endocrine tumours and neoplasia | ICEECE2012

Is combined radionuclide therapy with 90y-Dotatate and 177lu-Dotatate an effective treatment option for patients with metastasised neuroendocrine tumours? An ongoing study

Seregni E. , Vincenzo M. , Braud De F. , Buzzoni R. , Marco M. , Coliva A. , Pascali C. , Mallia A. , Bombardieri E.

Introduction: Neuroendocrine tumors (NETs) over-express somatostatin receptors (SRs) and the efficacy of peptide receptor radionuclide therapy (PRRT) with somatostatin analogues labeled with high activities of β-emitting radioisotopes has been reported.Aim: Ongoing study to evaluate efficacy and toxicity of combination treatment with 4 cycles of radiolabeled DOTATATE, alternating 177Lu and 90Yin patients with metastasised NETs expressing SRs refract...